1 July 2020 in Journal of Oncology Pharmacy Practice
The mean and median ages of diagnosis of multiple myeloma range from 70 to 73 years old, with 63% of patients being over the age of 65. Phase 3 clinical trials are designed to study efficacy in the target disease population and are meant to have the most representative subject pool. The purpose of this review is to identify the age demographic of subjects participating in interventional phase 3 clinical trials that aim to treat multiple myeloma and to determine if they encompass the true age demographic of the disease. To complete this review, a search of phase 3 multiple myeloma research trials with reported results was conducted on clinicaltrials.gov, a national, publicly available resource listing clinical trials. Reported mean or median ages of subjects were identified for each trial, and adjusted averages of these values were calculated. Data from 81 clinical trials were assessed, with 42 trials reporting an average mean age of 65.78 years and 15 trials reporting an average median age of 63.29 years. Based on these results, it was determined that the clinical trials reported in this study enrolled patients that were younger than the true age demographic of the disease. There is an unmet need in research in the older population of patients with multiple myeloma, and this may hinder the generalizability and utility of clinical trial results.
27 March 2026 in American Journal of Hematology
Data to guide management of isolated bland cancer‐associated splanchnic vein thrombosis (CA‐SpVT) are limited. We aimed to assess the role of anticoagulation (AC) and bleeding and thrombosis in patients with CA‐SpVT. We conducted a dual‐center retrospective cohort study of adults with incident, isolated, bland CA‐SpVT from 2011 to 2020. The primary outcome was major bleeding (MB); other outcomes included usual‐site venous thromboembolism (VTE) recurrence and progression/recanalization of CA‐SpVT. Time‐to‐event outcomes were analyzed with weighted Cox models adjusting for cancer type, stage, SpVT location, and whether symptomatic. For SpVT recanalization/progression, differences were estimated using weighted average treatment effects (ATEs). After excluding tumor thrombus, we included 437 patients with notable characteristics of median age 60 years, portal vein thrombosis (81.2%), and underlying hepatocellular cancer (35.9%). Of these, 29.5% received therapeutic AC. At 6 months, there were 11.9% MB and 6.4% incident usual‐site VTE events. Among 308 patients with follow‐up imaging, the 1‐year thrombus progression rate was 19.8% and thrombus recanalization was 28.6%. In the adjusted analysis, there were numerically higher rates of MB with AC (adjusted hazard ratio [aHR] 1.93, 95% confidence interval [CI] 0.97–3.87) and no significant difference in the incidence of VTE (aHR 1.41, 95% CI 0.56–3.51). AC was associated with significantly higher likelihood of venous recanalization (ATE +24% 95% CI 13%–35%) and significantly lower likelihood of thrombus progression (ATE –14% 95% CI –23% to −5%). In patients with isolated bland CA‐SpVT, AC was associated with thrombus recanalization and limited thrombus progression; effects were offset by a potentially higher risk of MB.
16 September 2025 in Antimicrobial Stewardship & Healthcare Epidemiology
This retrospective analysis compares the recovery rate of commensal organisms in two sets of blood cultures with a single-time stamp (STS) versus ones with multiple-time stamps (MTS) in an academic tertiary center. Rates in which both sets were positive for commensals were numerically higher in STS versus MTS.